BI works with Provectus on China candidate; Japan nods for Lantus XR, Harvoni;

> Boehringer Ingelheim will work to register cancer candidate PV-10 in China from U.S.-based Provectus ($PVCT) in return for priority rights in the country on commercialization. Release

> The latest exit from Ranbaxy Laboratories following its purchase by Sun Pharmaceutical completed this year sees head of Indian operations Rajeev Sibal exit, the Times of India reported. The newspaper says he is expected to join Lupin later this month to lead India and other emerging markets. Report

> Japan's Pharmaceutical and Medical Devices Agency approved Strensiq (asfotase alfa) from Alexion Pharmaceuticals ($ALXN) to treat hypophosphatasia, the company said in a statement. The therapy, which came through the Synageva BioPharma acquisition, is expected to be sold in Japan as soon as this quarter. Release

> Japan has approved Sanofi's ($SNY) next-generation basal insulin Lantus XR (insulin glargine) to treat Type 1 and Type 2 diabetes, the company said, marking the first Asian approval of the drug marketed as Toujeo in the U.S., Europe and Canada. Release

> Australia-listed Acrux and Eli Lilly ($LLY) filed a lawsuit in U.S. District Court against India's Lupin Pharmaceuticals for infringement of U.S. patents that cover axiron after a notice by Lupin to file an ANDA with the FDA for a testosterone-metered dose transdermal solution. Release (PDF)

> Japan has cleared the use of combination therapy Harvoni (ledipasvir/sofosbuvir) from Gilead Sciences ($GILD) to treat chronic hepatitis C virus (HCV) genotype 1 infection in adults, with or without compensated cirrhosis, in a once daily administration, the company said. Release

> Asian distributor Zuellig Pharma will exclusively sell South Korean firm Boryung Pharma's antihypertensive drug Kanarb (fimasartan) in 13 Southeast Asian countries. The company will pay $3 million in license fees to Boryung which also hopes for revenues of $126 million alone from Malaysia, Singapore, the Philippines, Indonesia, Thailand and Vietnam. Release

> Indian CRO GVK BioSciences announced plans to extend work with Australia's Akaal Pharma on AKP-11, a novel topical ointment, for a Phase II clinical study in psoriasis by providing clinical supplies and manufacturing and analytical support. Release

> Japan's Santen Pharmaceutical submitted an IND application to the U.S. FDA on July 1 for wet age-related macular degeneration candidate, anti-endoglin antibody DE-122, licensed from U.S.-based Tracon Pharmaceuticals ($TCON). If accepted, the drug is expected to receive a milestone payment of $3 million. Release (PDF)

> Japan's SymBio Pharmaceuticals said a Phase I study of oncology candidate SyB C-1101, rigosertib, showed favorable results. The company aims to participate in two multinational Phase III studies by U.S.-based Onconova Therapeutics ($ONTX), licensor of the compound, by early 2016. Release (PDF)

> China's Zhejiang Hisun Pharma told the Hong Kong Exchange that first half profit in 2015 likely fell 60% to 80% from RMB169.6 million ($27.32 million) a year ago as sales declined sharply. Release (Chinese language)

> NYSE-listed China's Nepstar Chain Drugstore ($NPD) said Chairman of the Board Simin Zhang has offered $1.30 per share--or $2.60 per American Depository Share--to take the company private using debt and/or equity. The board expects to form a special committee consisting of independent directors to consider the proposal. Release